Kent u de chatbox al? chat met andere beleggers


Inventiva Pharma

Beleggen in aandelenbeurzen Europa: DAX, FTSE 100, CAC40, etc.

beursfre
Forum actieveling
Forum actieveling
Berichten: 310
Lid geworden op: 02 mar 2018 15:26
waarderingen: 64
Contacteer:

Re: Inventiva Pharma

Bericht door beursfre »

Lama Daila schreef:
04 aug 2020 23:18
Is het nu wachten op het eerste rapport van een bank die niet betrokken is bij de IPO ? :D
ik denk dat iedereen nu wel gelooft dat het goed zit...
het enige wat nog kan helpen nu is een partner of samenwerking...
Biocartis (5,04€) - IBA (9,00€) - Inventiva (5,14€) - MDX (0,789€) - Mithra (20,05€) - Orange BE (14,90€) - Pharming (1,02€) - Exmar (2,10€) - Ontex (11,50€) - Telenet (33,96€) - Gensight Biologics (2,94€) - Acacia Pharma (2.07€) - Ageas (35,99€) - Innate Pharma (3,75€)





Volg Beursig.com op Twitter en Facebook

     


Stofke
Premiummember
Premiummember
Berichten: 996
Lid geworden op: 13 okt 2017 16:18
waarderingen: 576
Contacteer:

Re: Inventiva Pharma

Bericht door Stofke »

Gisteren ook opnieuw ingestapt
beursfre liked last!

Gebruikersavatar
Lama Daila
Forum elite
Forum elite
Berichten: 2147
Lid geworden op: 20 jul 2017 10:53
waarderingen: 3978
Contacteer:

Re: Inventiva Pharma

Bericht door Lama Daila »

Roth Capital: 32 EUR (ook betrokken bij IPO)
62CE7EE5-865D-4369-A59A-98E1DB5882AA.jpeg
Je hebt niet voldoende permissies om de bijlagen van dit bericht te bekijken.
VWarena liked last!
https://twitter.com/lama_daila

Gebruikersavatar
Lama Daila
Forum elite
Forum elite
Berichten: 2147
Lid geworden op: 20 jul 2017 10:53
waarderingen: 3978
Contacteer:

Re: Inventiva Pharma

Bericht door Lama Daila »

“ Jefferies LLC, Stifel, Nicolaus & Company, Incorporated and Guggenheim Securities, LLC acted as Joint Global Coordinators and bookrunners for the Offering. H.C. Wainwright & Co., LLC acted as lead manager and Roth Capital Partners, LLC and KBC Securities USA LLC acted as co-managers for the Offering (together, the “Underwriters”).”

Bijna alle koersdoelen van de Underwriters van de IPO kennen we nu ondertussen. Enkel Wainwright ontbreekt nog.
Vermoedelijk is de periode dat de analisten van deze Underwriters hun coverage moeten opschorten gisteren verlopen.
Gekko liked last!
https://twitter.com/lama_daila

beursfre
Forum actieveling
Forum actieveling
Berichten: 310
Lid geworden op: 02 mar 2018 15:26
waarderingen: 64
Contacteer:

Re: Inventiva Pharma

Bericht door beursfre »

amper bieders 11 voor mss 1500 aandelen samen
maar de ask zijde wordt lustig gekocht.
Biocartis (5,04€) - IBA (9,00€) - Inventiva (5,14€) - MDX (0,789€) - Mithra (20,05€) - Orange BE (14,90€) - Pharming (1,02€) - Exmar (2,10€) - Ontex (11,50€) - Telenet (33,96€) - Gensight Biologics (2,94€) - Acacia Pharma (2.07€) - Ageas (35,99€) - Innate Pharma (3,75€)

NewB76
Forum actieveling
Forum actieveling
Berichten: 895
Lid geworden op: 21 jul 2018 13:41
waarderingen: 200
Contacteer:

Re: Inventiva Pharma

Bericht door NewB76 »

IVA ADR gesloten met 4.49% op 11.87 $ en met een omzet van 220K vanavond

beursfre
Forum actieveling
Forum actieveling
Berichten: 310
Lid geworden op: 02 mar 2018 15:26
waarderingen: 64
Contacteer:

Re: Inventiva Pharma

Bericht door beursfre »

NewB76 schreef:
07 aug 2020 22:37
IVA ADR gesloten met 4.49% op 11.87 $ en met een omzet van 220K vanavond
das 10,07€
not bad...
hopelijk is da voor maandag :)
Biocartis (5,04€) - IBA (9,00€) - Inventiva (5,14€) - MDX (0,789€) - Mithra (20,05€) - Orange BE (14,90€) - Pharming (1,02€) - Exmar (2,10€) - Ontex (11,50€) - Telenet (33,96€) - Gensight Biologics (2,94€) - Acacia Pharma (2.07€) - Ageas (35,99€) - Innate Pharma (3,75€)

VWarena
Forum actieveling
Forum actieveling
Berichten: 902
Lid geworden op: 04 jun 2015 13:46
waarderingen: 545
Contacteer:

Re: Inventiva Pharma

Bericht door VWarena »

10,12€ op hoogte team USA ;)
Uitkijken nu naar opening @Nasdaq 8-)
Gekko liked last!

Gebruikersavatar
Lama Daila
Forum elite
Forum elite
Berichten: 2147
Lid geworden op: 20 jul 2017 10:53
waarderingen: 3978
Contacteer:

Re: Inventiva Pharma

Bericht door Lama Daila »

https://www.globenewswire.com/news-rele ... TRACT.html

DESCRIPTION OF THE SHARE BUYBACK PROGRAM & RESUMPTION OF THE LIQUIDITY CONTRACT

Pursuant to the authorization granted by the shareholders at the Combined General Meeting of May 28, 2020 and the Board of Directors' meeting held on June 22, 2020, Inventiva:

Confirms the terms and conditions of the share buyback program; and
Announces the resumption of the liquidity contract related to Inventiva shares and the end of the stabilization period


2020-2021 SHARE BUYBACK PROGRAM

As required under articles 221-1 et seq. And 241-1 et seq. of the General Regulations of the French Financial Markets Authority (Autorité des Marchés Financiers - AMF), this document sets out the objectives and terms and conditions of the share buyback program approved by Inventiva's shareholders and allowing for the subsequent renewal and resumption of the liquidity contract.

1. Date of the General Meeting at which the 2020-2021 share buyback program was authorized by shareholders

On May 28, 2020, the Combined General Meeting authorized, in its twelfth resolution, the Board of Directors to intervene on Inventiva's shares, the main characteristics of which are described below.

2. Allocation of treasury shares per objective of the share buyback program as of July 31, 2020


The 14,361 treasury shares held as of July 31, 2020, are allocated for the purpose of ensuring the liquidity or animating the market for Inventiva's shares through an investment service provider acting independently under a liquidity contract that complies with a code of ethics approved by the AMF.

Objectives of the share buyback program

setting-up and honoring obligations under stock option programs or other allocations of shares to the Company's employees and executive officers and, in particular, to allocate shares to the Company's employees and executive officers in the context of

profit sharing, or

any share purchase, stock option or free share allocation plan pursuant to applicable law, in particular Articles L.3331-1 et seq. of the French Labor Code (including any sale of shares referred to in Article L.3332-24 of the French Labor Code), and to carry out any hedging transactions relating to these transactions;

carrying-out purchase or sale transactions through a liquidity contract entered into an investment service provider, in accordance with the market practice accepted by the markets' authorities;

delivering the shares upon exercise of the rights attached to securities corresponding to debt instruments giving a claim to the Company's share capital through repayment, conversion, exchange, presentation of a warrant or in any other manner;
reducing the Company's capital by cancelling some or all the acquired shares;

more generally, performing all operations subsequently authorized by the laws or any market practice that may be authorized in the future under the market authorities.

Maximum percentage of share capital to acquire; maximum number, maximum purchase price and characteristics
Maximum proportion of capital that may be acquired 10% of the total number of shares making up Inventiva's capital, namely 3,839,301 shares based on the current capital.
Maximum of shares that may be held In accordance with Article L. 225-210 of the French Commercial Code, the number of shares held in treasury at any given time may not represent more than 10% of Inventiva's share capital at that date.
Maximum purchase price that may be bought back The maximum purchase price is set at €13 per share. As a reminder, the Board of Directors has the ability to adjust this amount in the event of transactions on the capital of Inventiva. The maximum amount that may be invested in the share buyback program by Inventiva is €5,000,000.

Characteristics of the shares that may be bought back The relevant securities are ordinary Inventiva shares listed on Euronext Paris (Compartiment B) under ISIN FR0013233012.

The acquisition, sale or transfer of these shares may be carried out and paid for by any methods within the limits allowed under applicable regulations or that may be authorized in the future, on a regulated market, a multilateral trading system, with a systematic internalizer or over-the-counter, in particular through block purchases or sales, or through the use of options or derivatives or, more generally, securities giving rights to shares of Inventiva.
5. Duration of the share buyback program

The share buyback program may be carried out at any time during the eighteen months following the Board of Directors meeting date on June 22, 2020 at which it was authorized, namely until December 22, 2021.

In accordance with Article 241-2, II of the AMF's General Regulations, while the share buyback program is in process, any significant change in any of the information provided in sections 3, 4, and 5 above will be publicly disclosed without delay, by the methods specified in Article 221-3 of the AMF's General Regulations.



RESUMPTION OF THE LIQUIDITY CONTRACT AND END OF THE STABILIZATION PERIOD



The liquidity contract related to Inventiva shares, which complies with the AMAFI code of ethics and approved by the AMF on March 21, 2011, entered into between Inventiva and Kepler Cheuvreux on January 19, 2018, as amended by an amendment dated February 6, 2019 and tacitly renewable, will expire on December 31, 2020 and will be tacitly renewed.

Inventiva announces today the resumption of this liquidity contract, which was suspended in the context of the initial public offering of Inventiva's shares in the form of American Depositary Shares on the Nasdaq, as of today. The period for the exercise of the overallotment option lasted from July 8 to August 7, 2020. The underwriters of the initial public offering, acting in the name and on behalf of Inventiva, have put an end to the stabilization period, as of today, and have not exercised the overallotment option.

As of August 7, 2020, the following means are allocated to the liquidity account for the execution of this contract:

14,361 Inventiva shares held on behalf of Inventiva,

€995,431.05.
VWarena liked last!
https://twitter.com/lama_daila

Gebruikersavatar
Lama Daila
Forum elite
Forum elite
Berichten: 2147
Lid geworden op: 20 jul 2017 10:53
waarderingen: 3978
Contacteer:

Re: Inventiva Pharma

Bericht door Lama Daila »

https://www.dailypolitical.com/2020/08/ ... seiva.html

Inventiva S.A. to Post FY2020 Earnings of ($0.94) Per Share, Jefferies Financial Group Forecasts (NYSE:IVA)
August 10th, 2020 - Comments Off on Inventiva S.A. to Post FY2020 Earnings of ($0.94) Per Share, Jefferies Financial Group Forecasts (NYSE:IVA) - Filed Under - by Patrick Bannon

Inventiva S.A. (NYSE:IVA) – Stock analysts at Jefferies Financial Group issued their FY2020 EPS estimates for Inventiva in a research note issued on Tuesday, August 4th. Jefferies Financial Group analyst L. Codrington forecasts that the company will post earnings of ($0.94) per share for the year. Jefferies Financial Group also issued estimates for Inventiva’s FY2021 earnings at ($1.76) EPS, FY2022 earnings at ($1.99) EPS, FY2023 earnings at ($2.11) EPS and FY2024 earnings at $10.76 EPS.

Tot 2023 dus EPS met haakje errond, wat betekent dat die nog negatief zijn, maar vanaf 2024 enorme jump omhoog
Terugnajaren liked last!
https://twitter.com/lama_daila

Deelnemen aan het forum + meer functies?

Discussieer met duizenden beleggers, minder
advertenties, ideaal voor smartphone, betere
gebruikservaring en gratis abonneren op favoriete
onderwerpen. Registreer binnen 1 minuut!


Plaats reactie